Trial Outcomes & Findings for Prospective Analysis of Value of Contrast-enhanced Sonography During Biopsies of Focal Liver Masses (NCT NCT03040323)

NCT ID: NCT03040323

Last Updated: 2019-08-08

Results Overview

Complication will be defined as 1) bleeding seen on post-biopsy CT or US, 2) drop in hemoglobin of more than 1.5 g/dL within one week after biopsy, or 3) need for hepatic artery embolization.

Recruitment status

TERMINATED

Study phase

PHASE4

Target enrollment

83 participants

Primary outcome timeframe

30 days

Results posted on

2019-08-08

Participant Flow

Insufficient patient recruitment and following internal IRB audit study was abandoned/terminated. The PI has left the institution and no information is available regarding how many participants Started and Completed the study in each arm

Participant milestones

Participant milestones
Measure
Biopsy With Lumason
Lumason 60.7Mg Powder for Injection injected prior to ultrasound-guided biopsy
Biopsy With Placebos
Placebos injected prior to ultrasound-guided biopsy.
Overall Study
STARTED
0
0
Overall Study
COMPLETED
0
0
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Prospective Analysis of Value of Contrast-enhanced Sonography During Biopsies of Focal Liver Masses

Baseline characteristics by cohort

Baseline data not reported

PRIMARY outcome

Timeframe: 30 days

Population: Insufficient patient recruitment and following internal IRB audit study was abandoned/terminated. No data were collected for Outcome Measures

Complication will be defined as 1) bleeding seen on post-biopsy CT or US, 2) drop in hemoglobin of more than 1.5 g/dL within one week after biopsy, or 3) need for hepatic artery embolization.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 30 days

Population: Insufficient patient recruitment and following internal IRB audit study was abandoned/terminated. No data were collected for Outcome Measures

Biopsy sample being sufficient for histological diagnosis and/or complete genotyping.

Outcome measures

Outcome data not reported

Adverse Events

Biopsy With Lumason

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Biopsy With Placebos

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Jordan Swensson ,MD

Indiana University Department of Radiology

Phone: 317-944-1831

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place